Chemical Component Summary | |
|---|---|
| Name | Psilocybin |
| Synonyms | [3-[2-(dimethylamino)ethyl]-1~{H}-indol-4-yl] dihydrogen phosphate |
| Identifiers | [3-[2-(dimethylamino)ethyl]-1~{H}-indol-4-yl] dihydrogen phosphate |
| Formula | C12 H17 N2 O4 P |
| Molecular Weight | 284.248 |
| Type | NON-POLYMER |
| Isomeric SMILES | CN(C)CCc1c[nH]c2c1c(ccc2)OP(=O)(O)O |
| InChI | InChI=1S/C12H17N2O4P/c1-14(2)7-6-9-8-13-10-4-3-5-11(12(9)10)18-19(15,16)17/h3-5,8,13H,6-7H2,1-2H3,(H2,15,16,17) |
| InChIKey | QVDSEJDULKLHCG-UHFFFAOYSA-N |
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 36 |
| Chiral Atom Count | 0 |
| Bond Count | 37 |
| Aromatic Bond Count | 10 |
Drug Info: DrugBank
| DrugBank ID | DB11664? |
|---|---|
| Name | Psilocybin |
| Groups | investigational |
| Description | Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA. |
| Synonyms |
|
| Categories |
|
| CAS number | 520-52-5 |
Related Resource References
| Resource Name | Reference |
|---|---|
| Pharos | CHEMBL194378 |
| PubChem | 138543650, 10624 |
| ChEMBL | CHEMBL194378 |
| ChEBI | CHEBI:8614 |
